Will Trump Really Take On Big Pharma?
- President Trump followed through on his campaign promises to impose tariffs on steel and aluminum imports.
- That made Trump's State of the Union statements on prescription drug overhaul all the more real.
- As Health Policy analyst Emily Evans explains, if Trump's prescription drug policies are enacted, it could have a drastic impact on big pharma.
After President Trump beat the drum on reducing prescription drug prices during this year's State of the Union address, some were skeptical about how serious the administration would be on fulfilling that promise.
Well, that initiative became a little "more real" after the president followed up on a prior promise and spooked global markets with a proposed 25% import tariff on foreign steel imports and 10% tariffs on aluminum.
Hedgeye Health Policy sector head Emily Evans explains that if Trump actually follows through on his prescription drugs idea, it would have drastic effects on the entire pharmaceutical industry.
"We took a good look at some of the policies coming out of the White House that suggest the Republican dominance of the government in Washington is not going to amount to a free pass for the pharmaceutical industry after all," Evans says in the video above.
Watch the full video for more.
This article was written by
Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.